Literature DB >> 24297881

Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.

Shih-Hon Li1, Ashley A Reinke, Karen L Sanders, Cory D Emal, James C Whisstock, Jeanne A Stuckey, Daniel A Lawrence.   

Abstract

Plasminogen activator inhibitor type-1 (PAI-1) is a member of the serine protease inhibitor (serpin) family. Excessive PAI-1 activity is associated with human disease, making it an attractive pharmaceutical target. However, like other serpins, PAI-1 has a labile structure, making it a difficult target for the development of small molecule inhibitors, and to date, there are no US Food and Drug Administration-approved small molecule inactivators of any serpins. Here we describe the mechanistic and structural characterization of a high affinity inactivator of PAI-1. This molecule binds to PAI-1 reversibly and acts through an allosteric mechanism that inhibits PAI-1 binding to proteases and to its cofactor vitronectin. The binding site is identified by X-ray crystallography and mutagenesis as a pocket at the interface of β-sheets B and C and α-helix H. A similar pocket is present on other serpins, suggesting that this site could be a common target in this structurally conserved protein family.

Entities:  

Keywords:  cancer; fibrinolysis; fibrosis; thrombolysis

Mesh:

Substances:

Year:  2013        PMID: 24297881      PMCID: PMC3870673          DOI: 10.1073/pnas.1216499110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding.

Authors:  I Verhamme; J O Kvassman; D Day; S Debrock; N Vleugels; P J Declerck; J D Shore
Journal:  J Biol Chem       Date:  1999-06-18       Impact factor: 5.157

2.  Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 A and full insertion of the reactive center loop into beta-sheet A.

Authors:  E Stratikos; P G Gettins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

3.  Implications for function and therapy of a 2.9 A structure of binary-complexed antithrombin.

Authors:  R Skinner; W S Chang; L Jin; X Pei; J A Huntington; J P Abrahams; R W Carrell; D A Lomas
Journal:  J Mol Biol       Date:  1998       Impact factor: 5.469

4.  The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.

Authors:  A M Sharp; P E Stein; N S Pannu; R W Carrell; M B Berkenpas; D Ginsburg; D A Lawrence; R J Read
Journal:  Structure       Date:  1999-02-15       Impact factor: 5.006

5.  Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.

Authors:  P Björquist; J Ehnebom; T Inghardt; L Hansson; M Lindberg; M Linschoten; M Strömqvist; J Deinum
Journal:  Biochemistry       Date:  1998-02-03       Impact factor: 3.162

6.  Solvent effects on activity and conformation of plasminogen activator inhibitor-1.

Authors:  P A Andreasen; R Egelund; S Jensen; K W Rodenburg
Journal:  Thromb Haemost       Date:  1999-03       Impact factor: 5.249

7.  Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens.

Authors:  J Neve; P A Leone; A R Carroll; R W Moni; N J Paczkowski; G Pierens; P Björquist; J Deinum; J Ehnebom; T Inghardt; G Guymer; P Grimshaw; R J Quinn
Journal:  J Nat Prod       Date:  1999-02       Impact factor: 4.050

8.  Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop.

Authors:  S Debrock; P J Declerck
Journal:  Thromb Haemost       Date:  1998-03       Impact factor: 5.249

9.  Modulation of plasminogen activator inhibitor 1 by Triton X-100--identification of two consecutive conformational transitions.

Authors:  A Gils; P J Declerck
Journal:  Thromb Haemost       Date:  1998-08       Impact factor: 5.249

10.  Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition.

Authors:  D J Pinsky; H Liao; C A Lawson; S F Yan; J Chen; P Carmeliet; D J Loskutoff; D M Stern
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

View more
  16 in total

1.  Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate.

Authors:  Ashley A Reinke; Shih-Hon Li; Mark Warnock; Maxim E Shaydakov; Naga Sandhya Guntaka; Enming J Su; Jose A Diaz; Cory D Emal; Daniel A Lawrence
Journal:  J Biol Chem       Date:  2018-12-03       Impact factor: 5.157

2.  Serpin latency transition at atomic resolution.

Authors:  Giorgia Cazzolli; Fang Wang; Silvio a Beccara; Anne Gershenson; Pietro Faccioli; Patrick L Wintrode
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

Review 3.  Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.

Authors:  Veronica R Placencio; Yves A DeClerck
Journal:  Cancer Res       Date:  2015-07-15       Impact factor: 12.701

4.  Innovative Non-PrP-Targeted Drug Strategy Designed to Enhance Prion Clearance.

Authors:  Arianna Colini Baldeschi; Marco Zattoni; Silvia Vanni; Lea Nikolic; Chiara Ferracin; Giuseppina La Sala; Maria Summa; Rosalia Bertorelli; Sine Mandrup Bertozzi; Gabriele Giachin; Paolo Carloni; Maria Laura Bolognesi; Marco De Vivo; Giuseppe Legname
Journal:  J Med Chem       Date:  2022-06-30       Impact factor: 8.039

5.  High-affinity binding of plasminogen-activator inhibitor 1 complexes to LDL receptor-related protein 1 requires lysines 80, 88, and 207.

Authors:  Mary Migliorini; Shih-Hon Li; Anqi Zhou; Cory D Emal; Daniel A Lawrence; Dudley K Strickland
Journal:  J Biol Chem       Date:  2019-12-02       Impact factor: 5.157

6.  Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.

Authors:  Machteld Sillen; Stephen D Weeks; Xiaohua Zhou; Andrey A Komissarov; Galina Florova; Steven Idell; Sergei V Strelkov; Paul J Declerck
Journal:  J Thromb Haemost       Date:  2020-02-20       Impact factor: 5.824

7.  Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1.

Authors:  Stéphane Pautus; Mouad Alami; Fréderic Adam; Guillaume Bernadat; Daniel A Lawrence; Allan De Carvalho; Gilles Ferry; Alain Rupin; Abdallah Hamze; Pierre Champy; Natacha Bonneau; Philippe Gloanec; Jean-Louis Peglion; Jean-Daniel Brion; Elsa P Bianchini; Delphine Borgel
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

8.  Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1.

Authors:  Katherine A Vousden; Tomas Lundqvist; Bojana Popovic; Brian Naiman; Alan M Carruthers; Philip Newton; Daniel J D Johnson; Anja Pomowski; Trevor Wilkinson; Patrick Dufner; Isabelle de Mendez; Philip R Mallinder; Clare Murray; Martin Strain; Jane Connor; Lynne A Murray; Matthew A Sleeman; David C Lowe; James A Huntington; Tristan J Vaughan
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

9.  A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase.

Authors:  Lihu Gong; Valerie Proulle; Chao Fang; Zebin Hong; Zhonghui Lin; Min Liu; Guangpu Xue; Cai Yuan; Lin Lin; Barbara Furie; Robert Flaumenhaft; Peter Andreasen; Bruce Furie; Mingdong Huang
Journal:  J Cell Mol Med       Date:  2016-05-20       Impact factor: 5.310

Review 10.  Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease.

Authors:  Breanne H Y Gibson; Matthew T Duvernay; Stephanie N Moore-Lotridge; Matthew J Flick; Jonathan G Schoenecker
Journal:  Res Pract Thromb Haemost       Date:  2020-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.